23andMe founder aims to restart auction with major corporate backing

23andMe founder Anne Wojcicki is seeking to restart the auction for the bankrupt genetic testing company, claiming to have backing from a Fortune 500 company with a market capitalization exceeding $400 billion. Wojcicki alleges that 23andMe's advisors unfairly capped her bid at $250 million, preventing a potential offer exceeding Regeneron's $256 million bid; 23andMe is seeking court approval for final proposals from Wojcicki and Regeneron by June 12, and a $10 million breakup fee for Regeneron if Wojcicki's bid prevails.

Analysis

The bankruptcy auction for genetic testing company 23andMe (MEHCQ.PK) is subject to a potential reopening, as founder Anne Wojcicki has requested judicial intervention, citing backing from an unnamed Fortune 500 company with a market capitalization exceeding $400 billion. This development introduces new uncertainty to Regeneron Pharmaceuticals' (REGN.O) existing $256 million agreement to acquire 23andMe. Wojcicki alleges that 23andMe's debtors manipulated the auction process, imposing an unfair $250 million cap on her bid via TTAM Research Institute and prematurely concluding the auction before a bid exceeding $280 million could be lodged. 23andMe, which declared bankruptcy in April due to diminished consumer interest and a significant 2023 data breach affecting millions, is now pursuing court permission for final proposals from both Wojcicki and Regeneron by June 12, alongside a proposed $10 million breakup fee payable to Regeneron if Wojcicki’s bid is successful. The per-ticker sentiment for MEHCQ.PK (-0.7) underscores its distressed situation amidst these M&A and legal complexities, while the overall market impact remains low (0.35).

Key Decisions for Investors

• Holders of MEHCQ.PK face a highly speculative situation; the potential for a superior offer by June 12, backed by a significant corporate entity, introduces upside, but the company's bankrupt status means recovery remains deeply uncertain.
• Regeneron investors should note the 23andMe acquisition attempt is minor relative to REGN's market capitalization; a failed bid would likely result in a $10 million breakup fee, limiting financial downside from this specific transaction.
• Interested parties should closely monitor the court's decision regarding the auction reopening and the outcome of the June 12 proposal deadline, as these events will be critical determinants of 23andMe's final sale price and potential recovery for stakeholders.